Laureate Pharma to Manufacture Neoprobe's MAb Product

October 7, 2009

Neoprobe Corporation (Dublin, OH) and Laureate Pharma, Inc. (Princeton, NJ) have entered into a Biopharmaceutical Development and Manufacturing Agreement.

Neoprobe Corporation (Dublin, OH) and Laureate Pharma, Inc. (Princeton, NJ) have entered into a Biopharmaceutical Development and Manufacturing Agreement. Under this agreement, Laureate will assist in the development and production of Neoprobe’s murine monoclonal antibody CC49 called RIGScan CR, a tumor-specific targeting agent initially intended for use in the treatment of colorectal cancer. Terms of the development and manufacturing agreement were not disclosed.